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Abstract
There are few studies of the association between placental malaria (PM) and mother-to-child
transmission (MTCT) of human immunodeficiency virus-1 (HIV-1), and the results of published
studies are inconsistent. To determine the association between PM and MTCT of HIV-1, we
performed a secondary analysis of data from a clinical trial of antibiotics to reduce
chorioamnionitis. Data regarding 1,662 HIV-1–infected women with live born singleton and first-
born twin infants with information regarding PM and infant HIV-1 infection status at birth were
analyzed. At the time of the study, women did not have access to antiretroviral drugs for treatment
of acquired immunodeficiency syndrome but had received nevirapine prophylaxis to reduce the
risk of MTCT of HIV-1. Placental malaria was not associated with the infant HIV-1 infection
status at birth ( P = 0.67). Adjustment for maternal plasma viral load and CD4+ cell count did not
change these results (odds ratio = 1.06, 95% confidence interval = 0.51–2.20, P = 0.87). Placental
malaria was more likely to be related to HIV-1 infection at birth among women with low viral
load at baseline (P for interaction = 0.08). In conclusion, PM was not associated with infant HIV-1
infection status at birth. The interaction of maternal plasma viral load, PM, and MTCT of HIV-1
warrants further studies.
INTRODUCTION
Infection with human immunodeficiency virus-1 (HIV-1) and malaria are among the most
prevalent infectious diseases worldwide. They disproportionately affect children and adults
in sub-Saharan Africa 1,2 where currently two-thirds of HIV-1 infections, 72% of acquired
immunodeficiency syndrome (AIDS)–related deaths, 1 and more than one million deaths
from malaria occur. 2 Both HIV-1 and malaria are associated with an increased risk of
adverse pregnancy outcomes, such as low birth weight, preterm birth, and stillbirth. 3 In the
absence of prenatal health services and interventions to prevent mother-to-child transmission
(MTCT) of HIV-1, an estimated 15–30% of HIV-1–infected pregnant women transmit the
virus to their infants during the in utero and intrapartum periods. 4,5 An estimated 25 million
pregnant women reside in malaria-endemic areas of sub-Saharan Africa and are at risk for
malarial infection each year. 6–8 Maternal malaria increases the risk of severe illness,
anemia, and death for the mother, and contributes to spontaneous abortion and stillbirth, and
is associated with preterm birth and low birth weight. 9–11
In addition to their respective disease manifestations, HIV-1 and malaria may interact
synergistically in co-infected individuals, and result in an increased risk of adverse health
outcomes. 10,12,13 In studies among pregnant women, the reported frequency and severity of
malaria 8,10,14–17 and risk of adverse pregnancy outcomes 18,19,22 were increased among
HIV-1–infected women compared with HIV-1–uninfected women. Infection with HIV-1
also has been identified as an independent predictor of malaria among pregnant
women. 8,9,15 For example, HIV-1 infection has been associated with an approximately two-
fold increase in the risk of having placental malaria (PM). 8,9 Additionally, an estimated
one-third to half of malaria infections were attributable to HIV-1 co-infection in a study
among HIV-1–infected pregnant women in Kenya. 16 Co-infection with HIV-1 and malaria
during pregnancy also has been associated with increased maternal viral load, 3,19–21 which
along with a lower maternal CD4+ cell count, is a known risk factor for MTCT of
HIV-1. 21–24
Four studies have examined the association between PM and MTCT of HIV-1, and the
findings have been inconsistent. A study in Rakai, Uganda, reported that PM was associated
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with a significantly increased risk of MTCT of HIV-1 after controlling for baseline maternal
viral load. 3 However, in studies conducted in Mombasa, Kenya, 14 Kisumu, Kenya, 25 and
Blantyre, Malawi, 21 no associations were observed between PM and in utero or peripartum
HIV-1 transmission. In contrast, in a study in western Kenya of women who were dually
infected with HIV-1 and malaria, higher parasitemia levels (≥ 10,000 parasites/μL of blood)
were associated with an increased risk of MTCT of HIV-1 (compared with lower
parasitemia levels). 26 In a detailed literature review, ter Kuile and others 8 concluded that
the available evidence was inconsistent with regard to an association between PM and
MTCT of HIV-1, and further studies were warranted. We examined the association between
PM and MTCT of HIV-1 among women and their infants enrolled in a large clinical trial
(HIVNET 024) conducted in Malawi, Zambia and Tanzania.
MATERIALS AND METHODS
Hivnet 024
HIVNET 024 was a Phase III, randomized, double-blind, placebo-controlled trial of
antibiotics to reduce chorioamnionitis-associated MTCT of HIV-1 and preterm birth. The
study protocol was reviewed and approved by the institutional review boards of all study
sites in the respective countries and the collaborating U.S. institutions. 27 The HIVNET 024
trial design and study population have been described in detail elsewhere. 27 Briefly, this
trial was conducted from July 2001 through August 2003 at four sites in three countries in
sub-Saharan Africa: Blantyre and Lilongwe, Malawi; Lusaka, Zambia; and Dar es Salaam,
Tanzania. After provision of HIV-1 voluntary counseling and testing and determination of
HIV-1 infection status, women were enrolled in the trial (at 20–24 weeks gestation) and
randomly assigned to receive either antibiotics (erythromycin and metronidazole antenatally
and ampicillin and metronidazole intrapartum) or placebo at 20–24 weeks’ gestation and at
the time of delivery. At three of the four sites, women not infected with HIV-1 also were
enrolled and randomized to reduce HIV-1–related stigmatization.
Routine prenatal care was provided to all participants. Fifty-two percent of women received
various antimalarial drugs as concomitant medications for clinical symptoms or they
received sulfadoxine-pyrimethamine as an intermittent preventive therapy during the second
and third trimester of pregnancy. In addition, all women received iron and folate
supplements, in accordance with the World Health Organization recommendations and
national standard of care guidelines in the respective study sites. Women and their infants
received nevirapine for prevention of MTCT of HIV-1 (HIVNET 012 regimen). 28
After enrollment, women were seen at 28 and 36 weeks gestation and at delivery. Maternal
sociodemographic information was recorded at baseline. Additionally, at follow-up visits,
physical examination was conducted, and obstetric and clinical histories were obtained.
Maternal laboratory examinations included HIV-1 diagnostic testing and CD4+ cell counts
at baseline (based on approved site-specific procedures) and measurement of plasma viral
load (at the University of North Carolina, Chapel Hill, NC, using the Roche HIV-1
Amplicor Monitor assay, version 1.5 [Roche, Branchburg, NJ]). 27 Infant HIV-1 diagnostic
testing was determined for live born infants at birth and at subsequent study visits using
blood samples collected on filter paper cards and examined as previously described 27 at the
University of North Carolina, Chapel Hill. Wherever possible, positive assays were
confirmed by analysis of a second blood sample that was collected at a subsequent follow-
up visit.
At delivery, placental, membrane, and umbilical cord samples were collected for histologic
examination. Placental samples were sent to the University Teaching Hospital in Lusaka,
Zambia, where all final processing and laboratory examinations were performed. To
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diagnose PM, formalin-fixed, paraffin-embedded placental tissue was prepared, cut at 5 μ,
and stained with hematoxylin and eosin. Diagnosis of PM was based on the presence of
trophozoites seen on Hematoxylin and eosin–stained slides but speciation was not
performed. In those cases where staining was negative, Giemsa staining was used to rule out
the presence of any malaria parasites. Other, more sensitive diagnostic techniques (e.g.,
histidine-rich protein [HRP-II] immunochemistry and polymerase chain reaction [PCR])
were not available in our setting. The pathologist reading the slides was not aware of the
clinical data. The PM parasite density was not determined because our interest was primarily
to establish whether the placenta was infected with malaria parasites or not.
Study population and definitions
The study population for this analysis comprised HIV-1–infected pregnant women enrolled
in the HIVNET 024 trial who had known delivery outcomes, a PM evaluation, and gave
birth to live born infants with available HIV-1 infection status. Only singletons and first-
born twins were included in the study population. Second-born twins were excluded because
HIV-1 infection status of the second twin was likely to be higher because of intrapartum
transmission and prolonged contact with maternal blood during delivery. Preterm infants
were defined as those born at less than 37 completed weeks gestation. Low birth weight was
defined as a birth weight < 2,500 grams.
Statistical analysis
Chi-square tests were performed to test for associations between categorical variables and
PM. Similarly, t tests were performed to compare the means and Wilcoxon tests to compare
the medians of continuous variables by PM status. We compared various background
characteristics between women with lower versus higher viral load at baseline. Statistical
analyses were performed to examine the association between PM and the infant’s HIV-1
infection status at birth. We assumed that any association between PM (an infection that
occurs sometimes during pregnancy) and MTCT of HIV-1 would most likely manifest itself
at birth (as opposed to later, e.g., at 6–8 weeks or thereafter). To estimate unadjusted and
adjusted odds of MTCT of HIV-1, a censored multinomial model was used, as previously
described. 29
We also determined the association between PM with monocytic infiltration in the placental
membranes, the decidua of placental floor, the villi, and infiltration at any of these three
sites. We further examined the effect of antibiotics compared with placebo on the presence
of monocytic infiltration, and on PM. Finally, we assessed whether the association of PM
with HIV-1 transmission was modified by the presence of lymphocytic infiltration.
Monocytic infiltration in the membranes, decidua of placental floor, or the villi, was
categorized as marked, slight, or not seen, and the chi-square or Fisher’s exact tests were
performed where appropriate to determine whether the associations were significant.
We developed multivariate analyses of the association between PM and HIV-1 transmission,
and included factors known to be potential confounders or that had P values < 0.2 in
univariate analyses. Multivariate models were adjusted for infant factors (preterm birth and
low birth weight) and maternal factors (trichomoniasis, bacterial vaginosis, CD4+ cell
counts, plasma viral load, and randomization arm). Plasma viral load values were
dichotomized into lower (< 55,000 copies/mL) and higher (≥ 55,000 copies/mL) values.
Plasma viral load values of ≥ 55,000 copies/mL) have been used to define advanced HIV-1
disease and as an indication for initiation of antiretroviral therapy. 30 Wald chi-square tests
were performed to test for significance of covariates. A sensitivity analysis was conducted to
assess the potential impact of missing data on the results. We conducted the analyses
described under two imputation methods: 1) multiple imputation, 31 and 2) a worst case
Msamanga et al. Page 4













scenario where a) all mothers who gave birth to HIV-1–infected infants and had missing PM
evaluations were imputed to be positive for malaria, and b) mothers with missing PM
evaluations and infants not infected with HIV-1 were assumed to be negative for malaria.
All statistical analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
Size and characteristics of the study population
Of 2,661 women randomized, 2,466 (92.7%) were followed until delivery. Of these, 2,126
women (86.2%) were infected with HIV-1 and had live-born infants (singletons or first-born
twins). Of these 2,126 women, PM evaluations were available for 1,750 women (82.3%) and
not available for 376 women (17.7%) ( Figure 1 ). The characteristics of these 2,126 women
according to whether a PM evaluation was available are shown in Table 1 . Those women
without a PM evaluation were slightly younger and were more likely to deliver a preterm,
lowbirth weight, or stillborn infant. The characteristics of the 1,750 women with PM
evaluations (and their infants), according to presence or absence of PM, are shown in Table
2 . Those women with PM were younger and had higher plasma viral load values. Their
infants had slightly lower gestational ages and birth weights. Of the 1,750 women with PM
evaluations, 1,662 (95%) had infants with HIV-1 diagnostic test results available from the
birth visit. Therefore, the study population comprised 1,662 mother-child pairs.
Characteristics of the study population according to maternal plasma viral load valu es are
shown in Table 3 . Compared with women with lower viral loads, those women with higher
plasma viral load values had less education, were more likely to be multiparous, had lower
hemoglobin values, had lower body mass indices, and lower CD4+ counts. Their infants
were more likely to be born preterm, have lower birth weights, and be female.
Malaria and MTCT of HIV-1
In univariate analyses, there were no significant differences in MTCT of HIV-1 according to
the presence or absence of PM ( P = 0.67). Of 1,662 mother–infant pairs, 6.3% (104 of
1,662) mothers had PM. Of the 104 infants whose mothers had PM, 8.7% (95% confidence
interval [CI] = 3.3–14.1) were infected with HIV-1 at birth compared with 7.5% of infants
of 1,558 mothers without PM (95% CI = 6.2–8.8). In multivariate analyses, PM was not
associated with HIV-1 infection status in the newborn (odds ratio [OR] = 1.06, 95% CI =
0.51–2.20, P = 0.87) ( Table 4 ) . In sensitivity analyses under the worst case scenario, the
odds of HIV-1 infection at birth for the presence of PM were 1.52 times the odds for the
absence of PM (OR = 1.52, 95% CI = 1.00–2.31, P = 0.05). Multiple imputation did not
provide evidence of a relationship between PM and HIV-1 infection at birth (OR = 1.19,
95% CI = 0.38–3.71, P = 0.77).
As expected, women with lower CD4+ counts and higher plasma viral loads were more
likely to transmit HIV-1 to their infants: a maternal plasma viral load ≥ 55,000 copies/mL
was significantly associated with a 2.3-fold increase (OR = 2.31, 95% CI = 1.55–3.44, P <
0.001) in the odds of HIV-1 infection in the newborn compared with a maternal viral load <
55,000 copies/mL. 28 Similarly, a maternal CD4+ cell count < 200 cells/μL was associated
with a 64% increase in the odds of HIV-1 infection in the newborn (OR = 1.64, 95% CI =
1.03–2.60, P = 0.04) compared with a maternal CD4+ cell count ≥ 350 cells/μL, and CD4+
cell counts of 200–350 cells/μL were not significantly associated with the HIV-1 infection
status of the newborn (OR = 0.96, 95% CI = 0.59–1.57, P = 0.88).
We examined the hypothesis that PM may be associated with higher monocytic infiltration
of the placenta, resulting in a higher risk of HIV-1 transmission. Women with PM had
higher monocytic infiltration in the decidua of the placental floor and membranes (55%)
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compared with women without PM (43%) ( P = 0.02). However, there was no association
between PM and monocytic infiltration of the membranes alone ( P = 0.77), of the placental
villi ( P = 1.0), or of any of the three sites ( P = 0.20). Compared with placebo, antibiotics
provided experimentally as part of the trial had no effect on the risk of monocytic infiltration
or PM, and the relationship between PM and HIV-1 transmission was not modified by the
presence of monocytic infiltration at any of the sites of the placenta.
Potential interactions between maternal viral load and PM
The potential interactions between maternal viral load and PM infection and their
relationship to HIV-1 infection at birth also were explored. Results from these analyses are
summarized in Table 5 . Placental malaria was more likely to be related to HIV-1 infection
at birth among women with lower viral load at baseline (P for interaction = 0.08). Among
women with viral loads < 55,000 copies/mL, the odds of HIV-1 infection at birth were 2.00
times greater for women with PM compared with women without placental malaria (OR =
2.00, 95% CI = 0.81–4.90, P = 0.14) Among women with viral loads ≥ 55,000 copies/mL,
the presence of PM was not associated with the risk of MTCT of HIV-1 ( P = 0.28).
DISCUSSION
In this prospective study of HIV-1–infected women, PM was not associated with MTCT of
HIV-1. Except for a recent study from Uganda, 22 the overall results of the current study are
consistent with studies in Malawi, 21 the Kenyan coast 25 and Kisumu. 26 Inconsistencies in
the results of previous studies of PM and MTCT of HIV-1 are likely caused by, at least in
part, to the epidemiology of malaria in different settings, which could affect maternal
immunity. Furthermore, these inconsistencies could be also be caused by differences in the
techniques that were used to diagnose PM (e.g., staining with hematoxylin and eosin, HRP-
II immunohistochemical staining, or PCR). Histologic examination is less sensitive
compared with HRP–II immunochemistry staining 22 and PCR, but these more sensitive
techniques were not available in our setting; use of low-sensitivity malaria diagnoses may
reduce the power to detect an association between PM and MTCT.
Maternal plasma viral load and CD4+ cell counts were associated with MTCT of HIV-1, as
has been demonstrated in previous studies. 22–25,32–35 Of greater interest, PM was associated
with higher risk of MTCT among women with low viral load and not among those with high
viral load. Women with lower viral load were more likely to be primgravidae, among whom
malaria tends to be more severe. Conversely, women with higher viral loads may have had
HIV-1 infection for a longer period, and being multigravid women, they may have
experienced malaria in previous pregnancies, resulting in partial pregnancy-specific
immunity to malaria.
The major strengths of the current analysis are the study design and the large sample size.
However, certain limitations should be considered. For example, only 80% of placental
samples were assessed for PM because of logistic constraints in collection, processing, and
examination of specimens at study sites. Placental samples were also missing from some
women who delivered away from the four study sites. Lack of availability of PM data was
associated with increased risk of preterm birth and infant low birth weight, factors that are
associated with MTCT of HIV-1. Women for whom PM data were not available were more
likely to have HIV-1–infected infants. These factors suggest that our findings may be biased
towards the null. Assessment of PM parasite density was not performed because we
examined the placentas primarily to determine whether the placentas were infected with
malaria or not. Density of PM parasites may be an important predictor of MTCT of
HIV-1. 26 Moreover, some women with low density malaria infections may have been
misclassified as negative for PM infections. As a result, potential non-differential
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misclassification of the exposure would be expected to bias findings towards the null
hypothesis. Assessment of malaria parasite density in future studies using more sensitive and
specific techniques may further the understanding of the relationship between PM and
MTCT of HIV-1.
Several mechanisms have been identified by which PM may affect MTCT of HIV-1. For
example, malarial infection may up-regulate HIV-1 CCR5 chemokine co-receptor
expression on placental macrophages, 35 and increase placental viral loads, 20 thereby
increasing the risk of HIV-1 transmission. Additionally, PM infection and subsequent
inflammatory responses may damage the integrity of the placenta and increase MTCT of
HIV-1. 3 Although we noted that PM was associated with monocytic infiltration in the
decidua of placental floor, no associations were noted with infiltration at other placental
sites, and in general infiltration did not modify the relation between PM and MTCT.
Unfortunately CC chemokines and cytokine measures were not available in this study, data
that could be obtained in future studies to shed more light on the inter-relationships of
malaria and HIV-1 infection. Malaria may also affect MTCT of HIV-1 indirectly, through its
adverse effects on maternal and infant immune function and pregnancy outcomes (e.g., low
birth weight). 18,19,22,36–38 For example, in a study in Zimbabwe, maternal malaria and
HIV-1 co-infection were independently associated with increased risks of low birth weight,
low Apgar scores, fetal growth restriction, and maternal, perinatal, and early infant
deaths. 18
The relationship between PM and MTCT of HIV-1 warrants further investigation, including
whether and how a maternal plasma viral load may modify this association. When we
conducted this study at the four sites in sub-Saharan Africa, study women who reached
advanced stages of HIV-1 did not have access to antiretroviral drugs for treatment of AIDS
as it is currently the case according to the national and international guidelines. However,
most women and their newborns were given nevirapine prophylaxis for prevention of
MTCT of HIV-1. Currently, several countries in sub-Saharan are scaling-up interventions to
prevent MTCT of HIV-1 and to improve care and treatment of HIV-1–infected women.
Whether PM affects the risk of MTCT of HIV-1 among HIV-1– infected women receiving
appropriate antiretroviral prophylaxis or treatment remains to be assessed.
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Table 1
Characteristics of 2,126 mother-child pairs, by availability of placental malaria evaluation
Characteristic Category Placental malaria evaluation available(n = 1,750)
Malaria evaluation not available (n =
376) P
Age, years Mean ± SE 25.4 ± 0.1 24.8 ± 0.3 0.02
Gestational age, weeks Mean ± SE 38.8 ± 0.1 37.6 ± 0.3 < 0.001
Hemoglobin, g/dL Mean ± SE 10.1 ± 0.03 10.2 ± 0.1 0.15
CD4+ cell count, cells/μL Mean ± SE 373 ± 6 375 ± 11 0.92
< 200 362/1,570 (23.1%) 68/345 (19.7%) 0.40
200–349 456/1,570 (29.0%) 104/345 (30.1%)
≥ 350 752/1,570 (47.9%) 173/345 (50.1%)
Plasma viral load, copies/mL Mean ± SE 4.3 ± 0.02 4.3 ± 0.04 0.18
< 55,000 1,163/1,663 (69.9%) 236/357 (66.1%) 0.15
≥ 55,000 500/1,663 (30.1%) 121/357 (33.9%)
Preterm birth No 1,334/1,750 (76.2%) 245/376 (65.2%) < 0.001
Yes 416/1,750 (23.8%) 131/376 (34.8%)
Birth weight, grams Mean ± SE 2,950 ± 14 2,848 ± 37 0.006
Low birth weight Yes 235/1,700 (13.8%) 53/269 (19.7%) 0.01
No 1,465/1,700 (86.2%) 216/269 (80.3%)
Stillborn Yes 47/1,750 (2.7%) 27/376 (7.2%) < 0.001
No 1,703/1,750 (97.3%) 349/376 (92.8%)
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Table 2
Characteristics of 1,750 mother-child pairs, according to presence or absence of placental malaria*
All (n = 1,750) Placental malarianegative (n = 1,643)
Placental malaria
positive (n = 107)
Characteristic Category % or Statistic % or Statistic % or Statistic P
Age, years Mean ± SE 25.4 ± 0.1 25.5 ± 0.1 24.3 ± 0.4 0.01
Education, years Median (Q1–Q3) 7.0 (5–9) 7.0 (5–9) 7.0 (3–8) 0.08
Parity Median (Q1–Q3) 3.0 (2–4) 3.0 (2–4) 3.0 (2–4) 0.92
CD4+ cell counts, cells/μL Mean ± SE 373 ± 6 374 ± 6 361 ± 20 0.56
< 200 362/1,750 (23.1%) 342/1,473 (23.2%) 20/97 (20.6%) 0.53
200–349 456/1,750 (29.0%) 423/1,473 (28.7%) 33/97 (34.0%)
≥ 350 752/1,750 (47.9%) 708/1,473 (48.1%) 44/97 (45.4%)
Plasma viral load (log) Mean ± SE 4.3 ± 0.02 4.3 ± 0.02 4.5 ± 0.07 0.001
Plasma viral load, copies/mL < 55,000 1,163/1,663 (69.9%) 1,101/1,558 (70.7%) 62/105 (59.1%) 0.01
≥ 55,000 500/1,663 (30.1%) 457/1,558 (29.3%) 43/105 (40.9%)
Hemoglobin, g/dL Mean ± SE 10.1 ± 0.03 10.1 ± 0.03 9.8 ± 0.2 0.05
Gestational age, weeks Mean ± SE 38.8 ± 0.1 38.8 ± 0.1 38.1 ± 0.3 0.04
Birth weight,† grams Mean ± SE 2,950 ± 14 2,961 ± 14 2,786 ± 54 0.002
Low birth weight† Yes 235/1,700 (13.8%) 216/1,594 (13.6%) 19/106 (17.9%) 0.21
No 1,465/1,700 (86.2%) 1,378/1,594 (86.4%) 87/106 (82.1%)
Stillborn Yes 47/1,750 (2.7%) 46/1,643 (2.8%) 1/107 (0.9%) 0.25
No 1,703/1,750 (97.3%) 1,597/1,643 (97.2%) 106/107 (99.1%)
Infant HIV-1 results Yes 1,662/1,703 (97.6%) 1,558/1,597 (97.6%) 104/106 (98.1%) 0.72
No 41/1,703 (2.4%) 39/1,597 (2.4%) 2/106 (1.9%)
*
Q1 = first quartile; Q3 = third quartile; HIV-1 = human immunodeficiency virus-1.
†
Not available for stillborn infants.
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Table 3
Characteristics of 1,662 mother-child pairs, according to maternal plasma viral load*












Characteristic Category % or Statistic % or Statistic % or Statistic % or Statistic P †
Maternal age, years Mean ± SE 25.4 ± 0.12 25.0 ± 0.58 25.3 ± 0.1 25.5 ± 0.2 0.39
Maternal education,
 years Median (Q1–Q3) 7.0 (5–9) 8.0 (6–9) 7.0 (5–9) 7.0 (4–9) 0.03
Parity Median (Q1–Q3) 3.0 (2–4) 2.5 (2–4) 3.0 (2–4) 3.0 (2–4) < 0.0001
1 285/1,662 (17.1%) 17/82 (20.7%) 198/1,108 (17.9%) 70/472 (14.8%) 0.0001
2 426/1,662 (25.6%) 24/82 (29.3%) 310/1,108 (28.0%) 92/472 (19.5%)
≥ 3 951/1,662 (57.2%) 41/82 (50.0%) 600/1,108 (54.2%) 310/472 (65.7%)
Gestational age,
 weeks Mean ± SE 39.0 ± 0.08 38.4 ± 0.3 39.3 ± 0.1 38.4 ± 0.2 < 0.0001
Hemoglobin, g/dL Mean ± SE 10.1 ± 0.03 10.3 ± 0.2 10.2 ± 0.04 9.8 ± 0.1 < 0.0001
Hemoglobin level < 7 32/1,645 (1.9%) 2/81 (2.5%) 19/1,097 (1.7%) 11/467 (2.4%) < 0.0001
7–8.5 158/1,645 (9.6%) 6/81 (7.4%) 91/1,097 (8.3%) 61/467 (13.1%)
8.5–11 1,015/1,645 (61.7%) 47/81 (58.0%) 662/1,097 (60.3%) 306/467 (65.5%)
≥ 11 440/1,645 (26.7%) 26/81 (32.1%) 325/1,097 (29.6%) 89/467 (19.1%)
Mean BMI, kg/m 2 Mean ± SE 23.3 ± 0.08 23.0 ± 0.31 23.6 ± 0.1 22.5 ± 0.1 < 0.0001
BMI, kg/m 2 < 18.5 44/1,662 (2.6%) 0/82 (0.0%) 24/1,108 (2.2%) 20/472 (4.2%) < 0.0001
18.5–25 1,233/1,662 (74.2%) 68/82 (82.9%) 791/1,108 (71.4%) 374/472 (79.2%) < 0.0001
25–30 328/1,662 (19.7%) 12/82 (14.6%) 244/1,108 (22.0%) 72/472 (15.3%)
≥ 30 57/1,662 (3.4%) 2/82 (2.4%) 49/1,108 (4.4%) 6/472 (1.3%)
CD4+ cell counts,
 cells/μL Mean ± SE 376 ± 7 362 ± 23 414 ± 7 287 ± 9 < 0.0001
< 200 339/1,493 (22.7%) 20/73 (27.4%) 161/998 (16.1%) 158/422 (37.4%) < 0.0001
200–349 434/1,493 (29.1%) 16/73 (21.9%) 281/998 (28.2%) 137/442 (32.5%)
≥ 350 720/1,493 (48.2%) 37/73 (50.7%) 556/998 (48.1%) 127/422 (30.1%)
Preterm birth, < 37
 weeks Yes 1,293/1,662 (77.8%) 58/82 (70.7%) 204/1,108 (18.4%) 141/472 (29.9%) < 0.0001
No 369/1,662 (22.2%) 24/82 (29.3%) 904/1,108 (81.6%) 331/472 (70.1%)
Birth weight,* grams Mean ± SE 2,975 ± 13 2,854 ± 64 3,037 ± 14.5 2,850 ± 27 < 0.0001
Low birth weight* Yes 209/1,659 (12.6%) 18/82 (22.0%) 104/1,105 (9.4%) 87/472 (18.4%) 0.0001
No 1,450/1,659 (87.4%) 64/82 (78.0%) 1,001/1,105 (90.6%) 385/472 (81.6%)
Newborn sex Male 844/1,661 (50.8%) 40/81 (49.4%) 583/1,108 (52.6%) 221/472 (46.8%) 0.03
Female 817/1,661 (49.2%) 41/81 (50.6%) 525/1,108 (47.4%) 251/472 (53.2%)
*
Q1 = first quartile; Q3 = third quartile; BMI = body mass index.
†
Chi-square test compared the last two columns of higher viral load with lower viral load, and the respective P values are presented.
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Table 4
Multivariate analyses of placental malaria and adjusted odds ratios of human immunodeficiency virus-1
infection status in the newborn*
Factor UnadjustedOR 95% CI P
Adjusted
OR 95% CI P
Placental malaria
 Yes 1.17 0.57–2.37 0.67 1.06 0.51–2.20 0.87
 No 1.00 – 1.00 –
CD4+ cell counts, cells/μL
 < 200 2.33 1.50–3.63 < 0.001 1.64 1.03–2.60 0.04
 200–350 1.08 0.66–1.76 0.77 0.96 0.59–1.57 0.88
 ≥ 350 1.00 – 1.00 –
Plasma viral load, copies/mL
 ≥ 55,000 2.78 1.92–4.04 < 0.001 2.31 1.55–3.44 < 0.001
 < 55,000 1.00 – 1.00 –
*
Multivariate models adjusted for plasma viral load, CD4+ cell counts, trichomoniasis, bacterial vaginosis, preterm birth, low birth weight, and
randomization arm. OR = odds ratio; CI = confidence interval.
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Table 5
Multivariate analyses of placental malaria and adjusted odds ratios of human immunodeficiency virus-1
infection status in the newborn within strata of baseline maternal plasma viral load*
Factor
Unadjusted
OR 95% CI P
Adjusted







 copies/mL 2.08 0.86–5.06 0.106 1.99 0.81–4.90 0.14
Viral load
 ≥ 55,000
 copies/mL 0.47 0.14–1.55 0.213 0.51 0.15– 1.74 0.28
*
Multivariate model adjusted for CD4+ cell counts, plasma viral load, trichomoniasis, bacterial vaginosis, preterm birth, low birth weight, and
randomization arm. OR = odds ratio; CI = confidence interval.
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